

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.


As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

FOE280' 6003E660




U937 mRNA Levels

Figure 1



U937 control PDE5

Figure 2




U937 5nm TPA 24hrs PDE5

Figure 3




U937 Control PDE2

Figure 4




U937 TPA 5nM 24hrs PDE2

Figure 5



cGMP and cAMP Hydrolysis in Permeabilized U937 Cells

Figure 6



U937 cells treated with 1 μ M compound 38. Apoptotic cells with active caspase 3 label red. Nuclear DNA label blue with DAPI.

Figure 8




Untreated U937 control cells. Apoptotic cells with active caspase 3 label red. Nuclear DNA label blue with DAPI.

Figure 9




U937 cells treated with 0.5uM Rolipram. Apoptotic cells with active caspase 3 label red.
Nuclear DNA label blue with DAPI.

Figure 10



U937 cells treated with 0.3nM Sildenafil. Apoptotic cells with active caspase 3 label red. Nuclear DNA label blue with DAPI.

Figure 11



TNFα media levels from U937 cells with or without compound 38 treatment.

Figure 12




Figure 13




Figure 14




Figure 15